Arginetix, Immune Control merge, raise $15 million

Arginetix Inc. (Baltimore, Md.) and Immune Control Inc. (West Conshohocken, Pa.) merged to form Corridor Pharmaceuticals Inc. and raised $15 million in a series A round. The combined company is developing therapies for vascular diseases, with an initial focus on pulmonary arterial hypertension (PAH). Corridor's lead candidate, C-122, is an oral small molecule inhibitor of serotonin receptors on activated immune cells in preclinical testing for PAH, with an IND submission expected next half. Arginetix CEO Gary Lessing becomes CEO of Corridor, while Immune Control CEO Stephen Roth becomes executive vice chairman. Corridor will be headquartered in Baltimore. ...